{"id":390961,"date":"2017-05-04T00:00:00","date_gmt":"2017-05-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0011-2017-biopharma-crohns-disease-current-treatment-physician-insights-eu5-2017\/"},"modified":"2026-03-31T09:01:06","modified_gmt":"2026-03-31T09:01:06","slug":"cutrim0011-2017-biopharma-crohns-disease-current-treatment-physician-insights-eu5-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0011-2017-biopharma-crohns-disease-current-treatment-physician-insights-eu5-2017\/","title":{"rendered":"Crohn&#8217;s Disease | Current Treatment: Physician Insights | EU5 | 2017"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>There are multiple well-established therapies available to treat Crohn\u2019s disease (<abbr title=\"Crohn's disease\">CD<\/abbr>). In particular, the mostly widely used biologics, the <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors (e.g., Janssen\/Merck\u2019s Remicade, AbbVie\/Eisai\u2019s Humira), helped to advance <abbr title=\"Crohn's disease\">CD<\/abbr> treatment, especially for moderate to severe patients. Over the past two years, the <abbr title=\"Crohn's disease\">CD<\/abbr> treatment landscape has witnessed the approval of two novel biologics (i.e., Takeda\u2019s Entyvio and Janssen\u2019s Stelara) and the launch of biosimilar infliximab (e.g., Celltrion\u2019s Remsima). Entyvio, the first and only cell adhesion molecule (<abbr title=\"cell adhesion molecule\">CAM<\/abbr>) inhibitor in the <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, offers an alternative treatment for <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 refractory patients; the recent approval of Stelara for <abbr title=\"Crohn's disease\">CD<\/abbr>, the first-in-class <abbr title=\"interleukin\">IL<\/abbr>-12\/23 inhibitor, also further expands physicians\u2019 treatment armamentarium. Indeed, the availability of these agents has influenced physicians\u2019 prescribing behavior, and will continue to impact the treatment landscape.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>\u00a0What drug classes are the patient share leaders across different lines of therapy? How are different biological agents positioned in surveyed physicians\u2019 treatment algorithm?<\/li>\n<li>\u00a0Under which scenarios do\/will physicians prescribe Stelara?<\/li>\n<li>What are the common treatment scenarios before initiating the different biological agents (i.e., Remicade, Humira, biosimilar infliximab, Entyvio, Stelara)? What is the course of action upon discontinuing these biological agents?<\/li>\n<li>What factors drive therapy discontinuation and switch? What factors have\/will drive recent\/anticipated prescribing changes?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p>Current Treatment: Physician Insights provides physician insights on treatment paths, prescribing behaviors, and the factors and perceptions driving brand usage so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.<\/p>\n","protected":false},"template":"","class_list":["post-390961","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-product-current-treatment","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390961\/revisions"}],"predecessor-version":[{"id":394084,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390961\/revisions\/394084"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}